JP2005529847A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529847A5
JP2005529847A5 JP2003565408A JP2003565408A JP2005529847A5 JP 2005529847 A5 JP2005529847 A5 JP 2005529847A5 JP 2003565408 A JP2003565408 A JP 2003565408A JP 2003565408 A JP2003565408 A JP 2003565408A JP 2005529847 A5 JP2005529847 A5 JP 2005529847A5
Authority
JP
Japan
Prior art keywords
conjugate
transporter
pharmaceutical composition
drug
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003565408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529847A (ja
Filing date
Publication date
Priority claimed from US10/351,291 external-priority patent/US20030158254A1/en
Application filed filed Critical
Publication of JP2005529847A publication Critical patent/JP2005529847A/ja
Publication of JP2005529847A5 publication Critical patent/JP2005529847A5/ja
Withdrawn legal-status Critical Current

Links

JP2003565408A 2002-01-24 2003-01-24 結腸トランスポーターによる治療用化合物の吸収の工作 Withdrawn JP2005529847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35180802P 2002-01-24 2002-01-24
US10/351,291 US20030158254A1 (en) 2002-01-24 2003-01-23 Engineering absorption of therapeutic compounds via colonic transporters
PCT/US2003/002206 WO2003065982A2 (en) 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters

Publications (2)

Publication Number Publication Date
JP2005529847A JP2005529847A (ja) 2005-10-06
JP2005529847A5 true JP2005529847A5 (https=) 2006-03-09

Family

ID=27737413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565408A Withdrawn JP2005529847A (ja) 2002-01-24 2003-01-24 結腸トランスポーターによる治療用化合物の吸収の工作

Country Status (7)

Country Link
US (1) US20030158254A1 (https=)
EP (1) EP1575494A2 (https=)
JP (1) JP2005529847A (https=)
KR (1) KR20040111348A (https=)
AU (1) AU2003244398A1 (https=)
CA (1) CA2473802A1 (https=)
WO (1) WO2003065982A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
JP4395070B2 (ja) * 2002-06-25 2010-01-06 インデックス・ダイアグノスティックス・アクチエボラーグ 潰瘍性大腸炎を診断するための方法およびキット
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
EP1651963A4 (en) * 2003-07-03 2007-03-21 Xenoport Inc MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
EP1677759A1 (en) * 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
US7462459B2 (en) * 2004-01-30 2008-12-09 Xenoport, Inc. LAT1 transporters expressed in blood brain barrier cells
US7452680B2 (en) * 2004-01-30 2008-11-18 Xenoport, Inc. MCT1 transporters expressed in blood brain barrier cells
WO2005117998A2 (en) * 2004-06-04 2005-12-15 Xenoport, Inc. Smvt transporters expressed in cancer cells
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20060003362A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. ENT1 transporters expressed in cancer cells
WO2005121787A2 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells
WO2006001986A2 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. Glut3 transporters expressed in cancer cells
US7348276B2 (en) * 2005-03-30 2008-03-25 Fujitsu, Limited Fabrication process of semiconductor device and polishing method
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
CN101534808A (zh) * 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
TWI403493B (zh) 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽,其組成物,及其用途
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
EP2217564A1 (en) * 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
CA2747253A1 (en) * 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
US9920136B2 (en) 2013-02-13 2018-03-20 Ark Diagnostics, Inc. Posaconazole immunoassays
BR112022026837A2 (pt) * 2020-07-01 2023-01-24 Capsugel Belgium Nv Composição e método dietético

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JP2002511777A (ja) * 1996-10-28 2002-04-16 ゼネラル ミルズ,インコーポレイテッド 調放性粒子の埋包およびカプセル化
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells

Similar Documents

Publication Publication Date Title
JP2005529847A5 (https=)
US11786491B2 (en) Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
JP3662942B2 (ja) 持続性放出甲状腺作用性組成物
ES2734523T3 (es) Combinaciones sinérgicas que comprenden un inhibidor de renina para enfermedades cardiovasculares
ES2849873T3 (es) Administración de fármacos gastrorretentivos de carbidopa/levodopa
JP2004534057A5 (https=)
CN117337174A (zh) 用于治疗癌症的包含cbd或thc的透皮药物制剂
CY1118794T1 (el) Διφασικη συνθεση κυστιδιων-λιπιδιων και μεθοδος για αγωγη τραχηλικης δυσπλασιας μεσω ενδοκολπικης απελευθερωσης
CY1107966T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii
CA2527646A1 (en) Abuse resistant amphetamine compounds
SA95160287A (ar) مركب صيدلي جديد للتعاطي بطريق الفم
IL173078A0 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
JP2009522370A5 (https=)
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
JP2010518086A5 (https=)
JP2006513184A5 (https=)
JP2006502187A5 (https=)
JP2013540795A (ja) 苦味のある薬物のための経口用医薬フィルム製剤
JP2005527505A (ja) 薬物血清レベルの患者間変動性を低減するためのペプチド−薬物複合体の使用
JP2005501010A5 (https=)
CA3041857A1 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
DE60317993D1 (de) Pharmazeutische Zubereitung mit verzögerter Freisetzung zur oralen Wirkstoffverabreichung
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
RU2006142101A (ru) Способ снижения желудочно-кишечной токсичности, возникающей в результате применения тегафура
CA2516327A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid